A novel approach to CFTR mutation testing by pyrosequencing-based assay panels adapted to ethnicities
| Autor: | Heidi Rossmann, Matthias Wiebel, Carolin Neukirch, Wolfgang Kamin, Jürgen J. Wenzel, Manfred Stuhrmann, Julia K. Bickmann, Friederike Häuser, Karl J. Lackner |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Genetics
medicine.diagnostic_test biology Base Sequence Cystic Fibrosis Genetic Carrier Screening Biochemistry (medical) Clinical Biochemistry Genetic disorder Cystic Fibrosis Transmembrane Conductance Regulator Sequence Analysis DNA medicine.disease Cystic fibrosis Polymerase Chain Reaction Cystic fibrosis transmembrane conductance regulator Cftr mutation Case-Control Studies Mutation (genetic algorithm) Mutation medicine biology.protein Pyrosequencing Humans Genotyping Sweat test |
| Zdroj: | Clinical chemistry. 55(6) |
| ISSN: | 1530-8561 |
| Popis: | Background: Cystic fibrosis (CF) is a common autosomal recessive genetic disorder caused by a variety of sequence alterations in the CFTR gene [cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)]. Because the relative prevalence of mutations strongly depends on the ethnic background, first-level testing of CF as defined by recent consensus recommendations ought to be adaptable to the ethnicity of patients. Methods: We therefore developed and implemented a diagnostic approach to first-level testing for CF based on published mutation frequencies and Pyrosequencing (PSQ) technology that we complemented with standard procedures of mutation detection at the second level. Results: The current test system of PSQ assays for 46 target CF mutations [including CFTRdele2,3 (21 kb) and 1342-6 (T)n (5T/7T/9T)] permits recombinations of single assays to optimize sensitivities for certain ethnicities. By easy expansion of the original mutation panel, the first-level test sensitivities with other ethnic groups would be increased, provided that the mutation frequencies are known. The test was validated with our local, ethnically mixed, but mainly German population (155 patients). The mutation-detection rate for the 92 patients whose CF was confirmed by the sweat test was 89.0% for the patients of German descent (73 of the 92 patients) and 73.7% for the patients of any other origin (19 of the 92 patients). Ethnicity-adapted testing panels for our foreign CF patients would increase the sensitivities for the respective groups by approximately 5%. Conclusions: PSQ-based genotyping is a reliable, convenient, highly flexible, and inexpensive alternative to conventional methods for first-level testing of CFTR, facilitating flexible adaptation of the analyzed mutation panel to any local ethnic group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|